ASP — Acerus Pharmaceuticals Share Price
Last Trade - 00:00- CA$61.50m
- CA$65.49m
- CA$1.17m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.1 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 24.49 | 6.54 | 7.38 | 3.77 | 1.08 | 52.01 | 69.42 | -42.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +5081.37 | n/a | n/a | n/a | n/a | n/a | +300 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a Canada-based pharmaceutical company. The Company is engaged in the development, manufacture, marketing and distribution of products with a focus on men's health, including urology, and women's health, including hormone replacement therapy and female sexual dysfunction. The Company markets Estrace in Canada, which is an oral, plant-derived 17-beta estradiol therapy for the relief of symptoms of menopause. The Company offers Natesto, which is the testosterone nasal gel in the United States for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). The Company offers TEFINA, which is a low-dose nasal testosterone gel treatment in development for female sexual dysfunction. The Company focuses on TriVair Deposition/Dispersion System, which is a unit dose dry powder inhaler and nasal dispersion system.
Directors
- Ian Ihnatowycz CHM (65)
- Edward Gudaitis
- Robert Motz
- Gavin Damstra
- Philippe Savard
- Borys Chabursky LED
- Geoff Cotton
- Stephen Gregory
- Scott Leckie
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- July 15th, 2009
- Public Since
- September 3rd, 2009
- No. of Employees
- 10
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 1,537,588,081
- Address
- 7025 Langer Drive, Suite 205, MISSISSAUGA, L5N 0E8
- Web
- http://www.aceruspharma.com/
- Phone
- +1 4167932740
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ASP
Upcoming events for ASP
Similar to ASP
BAUSCH HEALTH COMPAN ORD
Toronto Stock Exchange
CARDIOL THERAPEUTICS CL A ORD
Toronto Stock Exchange
CIPHER PHARMCEUTICALS ORD
Toronto Stock Exchange
CRESCITA THERAPEUTICS ORD
Toronto Stock Exchange
DELTA 9 CANNABIS ORD
Toronto Stock Exchange
FAQ
As of Today at 19:54 UTC, shares in Acerus Pharmaceuticals are trading at CA$0.04. This share price information is delayed by 15 minutes.
Shares in Acerus Pharmaceuticals last closed at CA$0.04 and the price had moved by -27.27% over the past 365 days. In terms of relative price strength the Acerus Pharmaceuticals share price has underperformed the Toronto Stock Exchange 300 Composite Index by -41.07% over the past year.
The overall consensus recommendation for Acerus Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Acerus Pharmaceuticals does not currently pay a dividend.
Acerus Pharmaceuticals does not currently pay a dividend.
Acerus Pharmaceuticals does not currently pay a dividend.
To buy shares in Acerus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.04, shares in Acerus Pharmaceuticals had a market capitalisation of CA$61.50m.
Here are the trading details for Acerus Pharmaceuticals:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: ASP
Based on an overall assessment of its quality, value and momentum Acerus Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Acerus Pharmaceuticals is CA$0.48. That is 1099.85% above the last closing price of CA$0.04.
Analysts covering Acerus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of CA$0.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acerus Pharmaceuticals. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -34.84%.
As of the last closing price of CA$0.04, shares in Acerus Pharmaceuticals were trading -10.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Acerus Pharmaceuticals.
Acerus Pharmaceuticals' management team is headed by:
- Ian Ihnatowycz - CHM
- Edward Gudaitis -
- Robert Motz -
- Gavin Damstra -
- Philippe Savard -
- Borys Chabursky - LED
- Geoff Cotton -
- Stephen Gregory -
- Scott Leckie -
We do not have data on Acerus Pharmaceuticals' shareholders